Hence, we selected AUR, an inhibitor of the TXN system that demonstrated activity against MLLr BCP-ALL PDXs in our previous studies [28] and has been shown to work independently of p53 in lymphoma models [24]. Here, TXN is linked to acute lymphoblastic leukemia.